Lionel de Hemptinne

Director of Finance/CFO at LUXEMPART

Finance

Consumer Non-Durables

Profile

Mr. Lionel de Hemptinne is a Chief Financial Officer at Luxempart SA. He is on the Board of Directors at Foyer SA. Mr. de Hemptinne was previously employed as a Chief Financial Officer by DROIA NV and a Chief Financial Officer & Secretary by La Floridienne NV.
He received his graduate degree from The Louvain School of Management and a graduate degree from Solvay Business School.

Lionel de Hemptinne active positions

Companies	Position	Start
LUXEMPART	Director of Finance/CFO	31/03/2022
FOYER SA	Director/Board Member	17/04/2023

All active positions of Lionel de Hemptinne

Former positions of Lionel de Hemptinne

Companies	Position	End
DROIA NV DROIA NV Droia Ventures invests in companies located across the globe. The firm focuses on oncology and gentic disease related drug development companies. It provides financing for seed and early stage capital requirements.	Director of Finance/CFO	29/04/2022
FLORIDIENNE S.A.	Director of Finance/CFO	30/04/2019

See the detail of Lionel de Hemptinne's experience

Training of Lionel de Hemptinne

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Lionel de Hemptinne's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	5
Luxempart SA Luxempart SA Financial ConglomeratesFinance Engages in the management and investment of portfolio of listed and unlisted companies	Finance
Foyer SA Foyer SA Multi-Line InsuranceFinance Provides life and non-life insurance & financial advisory services	Finance
La Floridienne NV La Floridienne NV Food: Specialty/CandyConsumer Non-Durables Operates as holding company with interest in manufacturing chemical products	Consumer Non-Durables
The Louvain School of Management The Louvain School of Management Functions as a College/University
DROIA NV DROIA NV Droia Ventures invests in companies located across the globe. The firm focuses on oncology and gentic disease related drug development companies. It provides financing for seed and early stage capital requirements.